Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress - Eli Lilly and Company
Eli Lilly reported a 48% revenue increase for Q2 2026, driven by strong sales of Mounjaro and Zepbound. The company raised its full-year guidance and announced significant progress in its clinical pipeline, including new regulatory approvals and upcoming obesity drug submissions.
Why it matters
As a major pharmaceutical player, Lilly's performance and pipeline updates significantly impact the healthcare sector and the competitive landscape for weight-loss medications.
LinkedIn Twitter Mail PDF Version Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume. Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAAP basis. Q2 2026 reported and non-GAAP EPS included $3.03 of acquired IPR&D charges compared to $0.14 in Q2 2025. Increased 2026 full-year revenue guidance to be in the range of $85.0 billion to $87.0 billion and raised underlying non-GAAP EPS guidance for the full year by $2.78 at the midpoint, which was more than offset by $3.03 of acquired IPR&D charges from Q2 business development activity, resulting in an updated range of $35.50 to $36.50 . Regulatory progress included U.S .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in